会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Measuring apparatus and measuring method
    • 测量装置和测量方法
    • US08487935B2
    • 2013-07-16
    • US12751453
    • 2010-03-31
    • Kazunori Aoki
    • Kazunori Aoki
    • G06T11/20G06T15/10G06T11/60G01R1/02
    • G06T11/206G01R1/025G01R13/0245G06T11/20G06T11/203G06T11/60
    • There is provided a technique for smoothly performing position (movement) adjustment of a waveform marker by making switching between rough adjustment and fine adjustment in a series of marker operations possible with a single means and continuously. A display control section displays a measured waveform on the two-dimensional coordinates, which have a first axis and a second axis perpendicular to the first axis, on the display section. A waveform marker is movable by a marker operation corresponding to a direction parallel to the first axis. The display control section has a detecting section, which detects the marker operation corresponding to a direction parallel to the second axis, and changes either setting of the waveform marker or the display range of the measured waveform according to the detection result of the detecting section.
    • 提供了一种通过使用单个装置连续地进行一系列标记操作中的粗调和微调之间的切换来平滑地执行波形标记的位置(移动)调整的技术。 显示控制部分在显示部分上显示具有与第一轴垂直的第一轴和第二轴的二维坐标上的测量波形。 波形标记可通过对应于与第一轴平行的方向的标记操作移动。 显示控制部分具有检测部分,其检测对应于与第二轴平行的方向的标记操作,并且根据检测部分的检测结果改变波形标记的设置或测量波形的显示范围。
    • 4. 发明申请
    • FEMALE COUPLING MEMBER AND MALE COUPLING MEMBER
    • 女性联合会员和男性联合会员
    • US20110037254A1
    • 2011-02-17
    • US12914227
    • 2010-10-28
    • Kazunori Aoki
    • Kazunori Aoki
    • F16L37/06
    • F16L37/42F16L37/0848F16L37/44F17C2205/037
    • A pipe coupling capable of being safely connected and disconnected. The pipe coupling has a tubular housing (16), a first locking member (18), a pressing member (24), a valve member (30), and a second locking member (50) provided between the valve member (30) and the pressing member (24). When the housing is communicated with a fluid source with the pressing member (24) placed in a standby position (FIGS. 1 to 4), the second locking member is displaced by the valve member, which is displaced toward an open position by fluid pressure. In this process, the second locking member engages with the pressing member (24) before the valve member reaches the open position (FIG. 2), thereby preventing the valve member from reaching the open position and, at the same time, preventing the pressing member from being displaced to a pressing position. When the housing is communicated with the fluid source with the pressing member (24) placed in the pressing position (FIG. 4), the second locking member does not engage with the pressing member and allows the valve member to be displaced to the open position.
    • 能够安全地连接和断开的管接头。 管接头具有管状壳体(16),第一锁定构件(18),按压构件(24),阀构件(30)和设置在阀构件(30)与第二锁定构件 按压构件(24)。 当壳体与压力构件(24)放置在待机位置(图1至图4)中的流体源连通时,第二锁定构件被阀构件移位,阀构件通过流体压力朝向打开位置移位 。 在该过程中,第二锁定构件在阀构件到达打开位置(图2)之前与推压构件(24)接合,从而防止阀构件到达打开位置,同时防止按压 成员从被转移到按压位置。 当壳体与压力构件(24)放置在按压位置(图4)中时与流体源连通时,第二锁定构件不与按压构件接合,并允许阀构件移动到打开位置 。
    • 6. 发明授权
    • Interferon alpha and antisense K-ras RNA combination gene therapy
    • 干扰素α和反义K-ras RNA组合基因治疗
    • US07514416B2
    • 2009-04-07
    • US11114088
    • 2005-04-26
    • Kazunori AokiTeruhiko Yoshida
    • Kazunori AokiTeruhiko Yoshida
    • A61K31/70
    • C12N15/1135A61K48/005C12N2310/11C12N2310/111C12N2320/31
    • Methods of suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation in a mammal, comprising: administering therapeutically effective amounts of adenoviral vector and antisense K-ras expressing vector to pancreatic cancer cells via intratumoral administration, wherein the adenoviral vector comprises a DNA sequence encoding a human IFN-alpha and operably linked to a promoter, and the pancreatic cancer cells to which the adenoviral vector is administered express the human IFN-alpha; and the antisense K-ras expressing vector comprises an antisense K-ras nucleotide sequence, wherein the antisense K-ras nucleotide sequence is operably linked to a promoter, and the pancreatic cancer cells to which the anti-sense K-ras expressing vector is administered express the antisense K-ras nucleotide sequence; whereby expression of the human IFN-alpha and the antisense K-ras nucleotide sequence suppress growth of pancreatic tumor or cancer cells in the mammal.
    • 抑制哺乳动物具有K-ras基因点突变的胰腺肿瘤或癌细胞生长的方法,包括:通过肿瘤内给药向胰腺癌细胞施用治疗有效量的腺病毒载体和反义K-ras表达载体,其中所述腺病毒载体 包括编码人IFN-α并可操作地连接到启动子的DNA序列,并且施用腺病毒载体的胰腺癌细胞表达人IFN-α; 并且反义K-ras表达载体包含反义K-ras核苷酸序列,其中反义K-ras核苷酸序列可操作地连接于启动子和施用反义K-ras表达载体的胰腺癌细胞 表达反义K-ras核苷酸序列; 由此人IFN-α和反义K-ras核苷酸序列的表达抑制哺乳动物胰腺肿瘤或癌细胞的生长。
    • 7. 发明申请
    • Interferon alpha and antisense K-ras RNA combination gene therapy
    • 干扰素α和反义K-ras RNA组合基因治疗
    • US20050260167A1
    • 2005-11-24
    • US11114088
    • 2005-04-26
    • Kazunori AokiTeruhiko Yoshida
    • Kazunori AokiTeruhiko Yoshida
    • A61K48/00C12N15/113
    • C12N15/1135A61K48/005C12N2310/11C12N2310/111C12N2320/31
    • An antiproliferative effect of IFN-α gene transduction in pancreatic cancer cells. The invention relates to expression of IFN-α to effectively induce growth suppression and cell death in pancreatic cancer cells, an effect which appeared to be more prominent when compared with other types of cancers and normal cells. Another aspect of the invention relates to targeting the characteristic genetic aberration, K-ras point mutation, in pancreatic cancer, and that the expression of antisense K-ras RNA significantly suppresses the growth of pancreatic cancer cells. When these two gene therapy strategies are combined, the expression of antisense K-ras RNA significantly enhanced IFN-α-induced cell death (1.3-3.5 fold), and suppressed subcutaneous growth of pancreatic cancer cells in mice. The invention also relates to a method of suppressing pancreatic cancer cells using double strand RNA formed by antisense and endogeneous K-ras RNA in combination with the anti-tumor activity of IFN-α. The invention relates to the combination of IFN-α and antisense K-ras RNA as an effective gene therapy strategy against pancreatic cancer. The invention also relates to a method of treating pancreatic cancer cells disseminated throughout the body by administering the inventive combination to localized pancreatic cancer cell tumor. The invention also relates to inducing indirect immunological antitumor activity to provide systemic immunity against pancreatic cancer cells.
    • IFN-α基因转导在胰腺癌细胞中的抗增殖作用。 本发明涉及IFN-α的表达,以有效诱导胰腺癌细胞的生长抑制和细胞死亡,与其他类型的癌症和正常细胞相比,这种作用似乎更加突出。 本发明的另一方面涉及靶向胰腺癌中的特征性遗传差异K-ras点突变,反义K-ras RNA的表达显着抑制胰腺癌细胞的生长。 当这两种基因治疗策略相结合时,反义K-ras RNA的表达显着增强了IFN-α诱导的细胞死亡(1.3-3.5倍),并抑制了小鼠胰腺癌细胞的皮下生长。 本发明还涉及使用由反义和内源K-ras RNA形成的双链RNA与IFN-α的抗肿瘤活性组合来抑制胰腺癌细胞的方法。 本发明涉及IFN-α和反义K-ras RNA的组合,作为对胰腺癌的有效基因治疗策略。 本发明还涉及通过将本发明组合施用于局部胰腺癌细胞肿瘤来治疗遍及全身的胰腺癌细胞的方法。 本发明还涉及诱导间接免疫抗肿瘤活性以提供对胰腺癌细胞的全身免疫。